Bayer also will be pushing more than 50 projects that focus on cardiovascular diseases, oncology, and women's health. The company highlighted two promising pipeline programs in mid-stage development: Factor XI (FXI)-targeting compounds, which are a new class of anticoagulants that is comprised of three investigational assets, and an anti-FXIa antibody and a FXI-ligand-conjugated antisense oligonucleotide (FXI-LICA) that are being studied in patients with end-stage kidney disease. FXI-pathway inhibition may offer protection from thromboembolic events without increased risk of bleeding.

CureVac, Bayer partner on COVID-19 vaccine
CureVac and Bayer have signed a collaboration and services agreement to develop a new class of medicines based on messenger RNA, starting with CureVac's...

Bayer, Atara collaborate on CAR T-cell therapies
Bayer and Atara Biotherapeutics have entered into an agreement to research, develop, manufacture, and license mesothelin-directed chimeric antigen receptor...

Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.

Specifica transfers antibody discovery platform to Bayer
Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based...